Synergic Medical Technologies

Synergic Medical Technologies operates in the neurotechnology and medical-device space, targeting motor-function impairment associated with Parkinson’s disease. Its stated differentiator is a non-invasive neuromodulation approach, alongside research focused on the relationship between altered brain activity and specific functional symptoms. The company reports FDA Breakthrough Device Designation for its device, a regulatory milestone that distinguishes its development profile but does not itself establish clearance, efficacy, or commercial availability. The product is described as being developed for Parkinson’s disease, rather than as a broad-purpose neuromodulation platform. At a category level, the treatment landscape includes medication, invasive approaches such as deep brain stimulation, and other non-invasive stimulation technologies; the meaningful competitive questions are likely to include evidence of motor-function benefit, safety, patient usability, and differentiation from existing care. No clinical outcomes or head-to-head comparisons are provided, limiting assessment of its relative position.

Founded in 2018, Synergic Medical Technologies is described as developing non-invasive neuromodulation for improving motor function, particularly in Parkinson’s disease. The company’s product remains framed as a technology in development; no product launch, clinical results, funding rounds, investor names, or valuation are established in its profile. The company’s trajectory therefore appears to depend on translating its research rationale into clinical evidence and subsequent regulatory and commercial progress. Key inflection points to watch would include disclosed trial initiation or results, further regulatory milestones, partnerships that support development or distribution, and a first commercial launch. Without dates or outcome data for these steps, the pace and financing of the company’s progress remain unclear.